Potential of St John's Wort for the treatment of depression: The economic perspective

Australian and New Zealand Journal of Psychiatry

Volumn 45, Issue 2, 2011, Pages 123-130

  Solomon, Daniela ^a   Ford, Emily ^a   Adams, Jon ^a   Graves, Nicholas ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

depression; economic evaluation; St John s wort

Indexed keywords

CITALOPRAM; CYTOCHROME P450 3A4; FLUOXETINE; GLYCOPROTEIN P; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; PAROXETINE; PLACEBO; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BLOOD CELL COUNT; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; HYPERICUM PERFORATUM; LIVER FUNCTION TEST; META ANALYSIS (TOPIC); PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SIDE EFFECT; TREATMENT WITHDRAWAL;

ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSION; DRUG COSTS; HUMANS; HYPERICUM; PHYTOTHERAPY; PLANT PREPARATIONS;

EID: 79951764728     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048674.2010.526094     Document Type: Article

References (109)

1. National Advisory Council on Mental Health. A mentally healthy future for all Australians . Canberra: National Advisory Council on Mental Health, 2009.
2. Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990 - 2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504. (Pubitemid 27216360)
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey replication. Arch Gen Psychiatry 2005; 62:593-602. (Pubitemid 40973434)
4. Welfare AIoHa. Australias Health 2008 . Canberra: Australian Institute of Health and Welfare, 2008.
5. Ernst E, Rand J, Stevinson C. Complementary therapies for depression. Arch Gen Psychiatry 1998; 55:1026-1032.
6. Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising survey data to informpublic policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry 2004; 184:526-533. (Pubitemid 38725713)
7. Kendrick T, Chatwin J, Dowrick C e t al . Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technology Assessment 2009; 13:1-198.
8. Bosmans J, Hermens M, de Bruijne M e t al . Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression. J Affect Disord 2007; 111:106-112.
9. Hollinghurst S, Shaw A, Thompson EA. Capturing the value of complementary and alternative medicine: including patient preferences in economic evaluation. Complement Ther Med 2008; 16:47-51. (Pubitemid 351372925)
10. Herman P, Craig B, Caspi C. Is complementary and alternative medicine (CAM) cost-effective? A systematic review. BMC Complement Altern Med 2005; 5.
11. Baker C, Woods S. Cost of treatment failure for major depression: direct costs of continued treatment. Adm Policy Ment Health 2001; 28:263-277.
12. Crown W, Finkelstein S, Berndt E et al . The impact of treatmentresistant depression on healthcare utilization and costs. J Clin Psychiatry 2002; 63:963-971.
13. Sullivan P, Valuck R, Saseen J, MacFall H. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18: 911-932. (Pubitemid 39612019)
14. Eisenberg D, Davis R, Ettner S et al . Trends in alternative medicine use in the United States, 1990 - 1997: results of a follow-up national survey. JAMA 1998; 280:1569-1575. (Pubitemid 28520643)
15. Eisenberg D, Kessler R, Foster C, Norlock F, Calkins D, Delbanco T. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993; 328: 246-252. (Pubitemid 23035311)
16. Hsu M-C, Creedy D, Moyle W, Venturato L, Tsay S-L, Ouyang W-C. Use of complementary and alternative medicine among adult patients for depression in Taiwan. J Affect Disord 2008; 111:360-365.
17. Hsu M-C, Moyle W, Creedy D, Venturato L, Ouyang W-C, Tsay S-L. Use of antidepressants and complementary and alternative medicine among outpatients with depression in Taiwan. Arch Psychiatr Nurs 2009; 23:75-85.
18. Kessler R, Soukup J, Davis R e t al . The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001; 158:289-294. (Pubitemid 32116527)
19. Knaudt P, Connor K, Weisler R, Churchill L, Davidson J. Alternative therapy use in psychiatric outpatients. Journal of Nervous and Mental Disease 1998; 187:692-695.
20. Wong A, Smith M, Boon H. Herbal remedies in psychiatric practice. Archives of General Psychiatry 1998; 55:1033-1045.
21. Knaudt P, Connor K, Weisler R, Churchill L, Erik M, Davidson J. Alternative therapy use by psychiatric outpatients. J Nerv Ment Dis 1999; 187:692-695.
22. Jacobs J, Crothers D. Who sees homeopaths? B r Homoeopath J 1991; 80:57-58.
23. Jansen G, Koster T. Complaints and diagnoses in homeopathic practice. Br Homoeopath J 1995; 84:140-143.
24. Gray C, Pronk N, OConnor P. Complementary and alternative medicine use among health plan members: a cross-sectional survey. Eff Clin Pract 2002; 5:17-22.
25. Kaufman D, Kelly J, Rosenberg I, Anderson T, Mitchell A. Recent patterns of medication use in the ambulatory adult population of the United States. The Slone survey. JAMA 2002; 287:337-344. (Pubitemid 34251967)
26. Fournier J, DeRubeis R, Hollon S e t al . Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303:47-53.
27. Kirsch I, Deacon B, Huedo-Medina T, Scoboria A, Moore T, Johnson B. Initial severity and antidepressant benefi ts: a metaanalysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5(2): e45.
28. K endrick T, Peveler R, Longworth L, Baldwin D, Moore M, Chatwin J et al . Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial. Br J Psychiatry 2006; 188:337-345.
29. Rapaport M, Judd L, Schettler P e t al . A descriptive analysis of minor depression. Am J Psychiatry 2002; 159:637-643. (Pubitemid 34274947)
30. Lee S, Walker J, Jakul L, Sexton K. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety 2004; 19:10-19. (Pubitemid 38294604)
31. Fisher P, Van Haselen R, Hardy K, Berkovitz S, McCarney R. Effectiveness gaps: a new concept for evaluating health service and research needs applied to complementary and alternative medicine. J Altern Complement Med 2004; 10:627-632. (Pubitemid 39167308)
32. Pittler M, Abbot N, Harkness E, Ernst E. Location bias in controlled clinical trials of complementary/alternative therapies. J Clin Epidemiol 2000; 53:485-489. (Pubitemid 30254344)
33. Linde K, Berner M, Kriston L. St John s wort for major depression. Cochrane Database of Systematic Reviews 2008; 4: CD000448.
34. Pittler M, Abbot N, Harkness E, Ernst E. Location bias in controlled clinical trials of complementary/alternative therapies. J Clin Epidemiology 2000; 53:485-489. (Pubitemid 30254344)
35. Brevoort P. The blooming U.S. botanical market: a new overview. Herbalgram 1998; 44:33-46.
36. Carpenter C, Crigger N, Kugler R, Loya A. H ypericum and nurses: a comprehensive literature review on the effi cacy of St. Johns Wort in the treatment of depression. J Holist Nurs 2008; 26:200 - 207; discussion 208-211.
37. Ni H, Simile C, Hardy A. Utilization of complementary and alternative medicine by United States adults: results from the 1999 National Health Interview Survey. Med Care 2002; 40:353-358.
38. Linde K. St. Johns wort: an overview. F orsch Komplementarmed 2009; 16:146-155.
39. Butterweck V. Mechanism of action of St. Johns wort in depression: what is known? CNS Drugs 2003; 17:539-562. (Pubitemid 36774135)
40. Zanoli P. Role of hyperforin in the pharmacological activities of St. Johns wort. CNS Drug Rev 2004; 10:203-218. (Pubitemid 39391315)
41. Hammerness P, Basch E, Ulbricht C e t al . St. John s wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003; 44:271-282. (Pubitemid 36750533)
42. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St Johns wort for depression: an overview and metaanalysis of randomised clinical trials. Br Med J 1996; 313:253-258. (Pubitemid 26254730)
43. Gaster B, Holroyd J. St John s wort for depression: a systematic review. Arch Intern Med 2000; 160:152-156. (Pubitemid 30054333)
44. Whiskey E, Wernecke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int Clin Psychopharmacol 2001; 16:239-252. (Pubitemid 32822443)
45. Lawvere S, Mahoney M. St Johns wort. A m Fam Physician 2005; 72:2249-2254.
46. Clement K, Covertson C, Johnson M, Dearing K. St John s wort and the treatment of mild to moderate depression: a systematic review. Holist Nurs Pract 2006; 20:197-203.
47. Shelton R, Keller M, Gelenberg A et al . Effectiveness of St Johns wort in major depression: a randomized controlled trial. JAMA 2001; 285:1978-1986. (Pubitemid 32366950)
48. Gastpar M, Singer A, Zeller K. Comparative effi cacy and safety of a once-daily dosage of Hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Psychopharmacology 2006; 39:66-75.
49. Fava M, Alpert J, Nierenberg A e t al . A double-blind, randomized trial of St Johns wort, fl uoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005; 25:441-447. (Pubitemid 41368366)
50. Behnke K, Jensen G, Graubaum H, Gruenwald J. H ypericum perforatum versus fl uoxetine in the treatment of mild to moderate depression. Adv Ther 2002; 19:43-52. (Pubitemid 34438986)
51. van Gurp G, Meterissian G, Haiek L, McCusker J, Bellavance F. St Johns wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician 2002; 48:905-912. (Pubitemid 34678961)
52. Schrader E. Equivalence of St Johns wort extract (Ze 117) and fl uoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000; 15:61-68. (Pubitemid 30142797)
53. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. Johns wort extract LoHyp-57 and fl uoxetine. Arzneimittelforschung 1999; 49:289-296. (Pubitemid 29198106)
54. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther 2000; 22:411-419. (Pubitemid 30304793)
55. Rahimi R, Nikfar S, Abdollahi M. Effi cacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a metaanalysis. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:118-127.
56. National Institute for Health and Clinical Excellence. D epression: the treatment and management of depression in adults. National Clinical Practice Guideline 90 London: National Institute for Health and Clinical Excellence 2009:1-585.
57. Philipp M, Kohnen R, Hiller K. H ypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Br Med J 1999; 319:1534-1539.
58. Thornett A. Use of H ypericum as antidepressant. Valid measure of antidepressant effi cacy in primary care is needed. Br Med J 2000; 320:1141.
59. Hypericum Depression Trial Study Group. Effect of H ypericum perforatum (St Johns wort) in major depressive disorder: a randomised controlled trial. JAMA 2002; 287:1807-1814.
60. Anghelescu I, Kohnen R, Szegedi A, Klement S, Kieser M. Comparison of Hypericum extract WS5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomised multicenter study. Pharmacopsychiatry 2006; 39:213-219. (Pubitemid 44899722)
61. Gastpar M, Singer A, Zeller K. Effi cacy and tolerability of Hypericum extract STW3 in long term treatment with a once daily dosage in comparison with sertraline. Pharmacopsychiatry 2005; 38:78-87.
62. Brattstrom A. Long-term effects of St. John s wort (H ypericum perforatum ) treatment: A 1-year safety study in mild to moderate depression. Phytomedicine 2009; 16:277-283.
63. Gelenberg A, Shelton R, Crits-Christoph P e t al . The effectiveness of St. Johns Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. J Clin Psychiatry 2004; 65:1114-1119.
64. Kasper S, Volz HP, Moller HJ, Dienel A, Kieser M. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression - A double-blind, randomized, placebo controlled long-term trial. Eur Neuropsychopharmacol . 2008; 18: 803-813.
65. Sarris J. Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytother Res 2007; 21:703-716. (Pubitemid 47217768)
66. Whitten D, Myers S, Hawrelak J, Wohlmuth H. The effects of St Johns wort extracts on Cy3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 2006; 62:512-526. (Pubitemid 44571572)
67. Sarris J, Kavanagh D, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J Psychiatr Res 2009; 44:32-41.
68. Knuppel L, Linde K. Adverse effects of St. Johns wort: a systematic review. J Clin Psychiatry 2004; 65:1470-1479.
69. Finfgeld D. Serotonin syndrome and the use of SSRIs. J Psychosoc Nurs Ment Health Serv 2004; 42:16-20.
70. Izzo A, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69:1777-1798.
71. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. Johns wort drug interactions. Eur J Clin Pharmacol 2006; 62:225-233. (Pubitemid 43357581)
72. Zhou S. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9:310-322. (Pubitemid 351836420)
73. National Institute of Clinical Excellence. D epression: management of depression in primary and secondary care. NICE Clinical Guideline No. 23 . London: National Institutes of Health, 2004.
74. Hughes D, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10:601-615. (Pubitemid 32998372)
75. Burke M, Silkey B, Preskorn S. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry 1994; 55SA:42-52.
76. Thompson D, Buesching D, Gregor K, Oster G. Patterns of antidepressant use and their relation to cost of care. Am J Manag Care 1996; 2:1239-1246. (Pubitemid 126477345)
77. Sheehan D, Eaddy M, Sarnes M, Vishalpura T, Regan T. Evaluating the economic consequences of early antidepressant treatment discontinuation. J Clin Psychopharmacol 2004; 24:544-548.
78. Cantrell C, Eaddy M, Shah M, Regan T, Sokol M. Methods for evaluating patient adherence to antidepressant therapy: a realworld comparison of adherence and economic outcomes. Med Care 2006; 44:300-303. (Pubitemid 43755432)
79. Johnson D. Non-compliance with antidepressant therapy: an underestimated problem. Intern Med 1986; 11:14-17.
80. Johnson D. Depression: treatment compliance in general practice. Acta Psychiatr Scandinav 1981; 63:968-972.
81. Frazer A. Antidepressants. J Clin Psychiatry 1997; 58:9-25. (Pubitemid 27310165)
82. Nierenberg A, Wright E. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999; 60: 7-11. (Pubitemid 30107949)
83. Rascati K, Godley P, Pham H. Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. J Manag Care Pharm 2001; 7:402-406.
84. Kim H, Strelzer J, Goebert D. St Johns wort for depression: a meta-analysis of well-defi ned clinical trials. J Nerv Ment Dis 1999; 187:532-539.
85. Linde K, Knüppel L. Large-scale observational studies of H ypericum extracts in patients with depressive disorders: a systematic review. Phytomedicine 2005; 12:148-157. (Pubitemid 40174344)
86. Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001; 8: 152-160. (Pubitemid 32267101)
87. Woelke H, Burkhard G, Grunwald J. Benefi ts and risks of the Hypericum extract LI 160: drug-monitoring study with 3 250 patients. J Geriatr Psychiatry Neurol 1994; 7S1:34-38.
88. Schrader E, Meier B, Brattstrom A. H ypericum treatment of mild-moderate depression in a placebo- controlled study. Hum Psychopharmacol 1998; 13:163-169.
89. Vorbach E, Hubner W, Arnoldt K. Effectiveness and tolerance of the Hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. J Geriatr Psychiatry Neurol 1994; 7S1:S19 - 23. (Pubitemid 24330526)
90. Harrer G, Hubner W, Podzuweit H. Effectiveness and tolerance of the Hypericum extract LI 160 compared to maprotiline: a multicenter double blind study. J Geriatr Psychiatry Neurol 1994; 7S1:S24 - 28. (Pubitemid 24330527)
91. Wheatley D. LI 160, an extract of St. Johns wort, versus amitriptyline in mildly to moderately depressed outpatients: a controlled 6-week clinical trial. Pharmacopsychiatry 1997; 30S2:77-80.
92. Vorbach E, Arnoldt K, Hubner W. Effi cacy and tolerability of St. Johns wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Psychopharmacology 1997; 30S2:81-85.
93. Brockmoller J, Reum T, Bauer S, Kerb R. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30S2:94-101.
94. Schulz V. Safety of St John s wort extract compared to synthetic antidepressants. Phytomedicine 2006; 13:199-204. (Pubitemid 43120322)
95. Gupta R, Moller H. St John s wort: an option for the primary care treatment of depressive patients? European Archives of Clinical Neuroscience 2003; 253:140-148. (Pubitemid 37205473)
96. Hoencamp E, Stevens A, Haffmans J. Patientsattitudes towards antidepressants. Psychiatr Serv 2002; 53:1180-1181.
97. Loh A, Leonhart R, Wills C, Simon D, Harter M. The impact of patient participation on adherence and clinical outcome in primary care of depression. Patient Educ Couns 2007; 65:69-78. (Pubitemid 44820753)
98. Dijkstra A, Jaspers M. Psychiatric and psychological factors in patient decision making concerning antidepressant use. J Consult Clin Psychol 2008; 76:149-157. (Pubitemid 351215338)
99. van Schaik D, Klijn A, Van Hout H e t al . Patients preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiatry 2003; 26:184-189.
100. Australian Institute of Health and Welfare. A ustralias Health 2008 . Canberra: Australian Institute of Health and Welfare, 2008.
101. Lam R, Kennedy S, Grigoriadis S et al . Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117S:26-43.
102. Taylor C, Chang V. Issues in the dissemination of cognitive behavior therapy. Nordic Journal of Psychiatry 2008; 62S47:37-44.
103. Heuzenroeder L, Donnelly M, Haby M e t al . Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust N Z J Psychiatry 2004; 38:602-612. (Pubitemid 39199487)
104. Vos T, Corry J, Haby M e t al . Cost-effectiveness of cognitivebehavioural therapy and drug interventions for major depression. Aust N Z J Psychiatry 2005; 39:683-692. (Pubitemid 43904370)
105. Gerhards S, de Graaf L, Jacobs L e t al . Economic evaluation of online computerised cognitive-behavioural therapy without support for depression in primary care: randomised trial. Br J Psychiatry 2010; 196:310-318.
106. McCrone P, Knapp M, Proudfoot J et al . Cost-effectiveness of computerised cognitive - behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 2004; 185:55-62. (Pubitemid 38951630)
107. de Graaf LE, Gerhards SAH, Arntz A et al . Clinical effectiveness of online computerised cognitive-behavioural therapy without support for depression in primary care: randomised trial. Br J Psychiatry 2009; 195:73-80.
108. van Straten A, Seekles W, van t Veer-Tazelaar N, Beekman A, Cuijpers P. Stepped care for depression in primary care: what should be offered and how? Med J Aust 2010; 192S: 36-39.
109. Castle D, Schweitzer I, Tiller J. STAR*D: has it taught us anything about the management of depression? Australas Psychiatry 2009; 17:360-364.